These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

531 related items for PubMed ID: 24029138

  • 1. Clinical sequelae after rhBMP-2 use in a minimally invasive transforaminal lumbar interbody fusion.
    Singh K, Nandyala SV, Marquez-Lara A, Cha TD, Khan SN, Fineberg SJ, Pelton MA.
    Spine J; 2013 Sep; 13(9):1118-25. PubMed ID: 24029138
    [Abstract] [Full Text] [Related]

  • 2. Transforaminal lumbar interbody fusion with rhBMP-2 in spinal deformity, spondylolisthesis, and degenerative disease--part 2: BMP dosage-related complications and long-term outcomes in 509 patients.
    Crandall DG, Revella J, Patterson J, Huish E, Chang M, McLemore R.
    Spine (Phila Pa 1976); 2013 Jun 01; 38(13):1137-45. PubMed ID: 23354111
    [Abstract] [Full Text] [Related]

  • 3. Promoting fusion in minimally invasive lumbar interbody stabilization with low-dose bone morphogenic protein-2--but what is the cost?
    Mannion RJ, Nowitzke AM, Wood MJ.
    Spine J; 2011 Jun 01; 11(6):527-33. PubMed ID: 20739225
    [Abstract] [Full Text] [Related]

  • 4. Comparison of transforaminal lumbar interbody fusion outcomes in patients receiving rhBMP-2 versus autograft.
    Khan TR, Pearce KR, McAnany SJ, Peters CM, Gupta MC, Zebala LP.
    Spine J; 2018 Mar 01; 18(3):439-446. PubMed ID: 28822825
    [Abstract] [Full Text] [Related]

  • 5. Transforaminal lumbar interbody fusion with rhBMP-2 in spinal deformity, spondylolisthesis, and degenerative disease--part 1: Large series diagnosis related outcomes and complications with 2- to 9-year follow-up.
    Crandall DG, Revella J, Patterson J, Huish E, Chang M, McLemore R.
    Spine (Phila Pa 1976); 2013 Jun 01; 38(13):1128-36. PubMed ID: 23370679
    [Abstract] [Full Text] [Related]

  • 6. Complications of rhBMP-2 utilization for posterolateral lumbar fusions requiring reoperation: a single practice, retrospective case series report.
    Hoffmann MF, Jones CB, Sietsema DL.
    Spine J; 2013 Oct 01; 13(10):1244-52. PubMed ID: 23973099
    [Abstract] [Full Text] [Related]

  • 7. Symptomatic ectopic bone formation after off-label use of recombinant human bone morphogenetic protein-2 in transforaminal lumbar interbody fusion.
    Chen NF, Smith ZA, Stiner E, Armin S, Sheikh H, Khoo LT.
    J Neurosurg Spine; 2010 Jan 01; 12(1):40-6. PubMed ID: 20043763
    [Abstract] [Full Text] [Related]

  • 8. Prospective, randomized, controlled trial of silicate-substituted calcium phosphate versus rhBMP-2 in a minimally invasive transforaminal lumbar interbody fusion.
    Nandyala SV, Marquez-Lara A, Fineberg SJ, Pelton M, Singh K.
    Spine (Phila Pa 1976); 2014 Feb 01; 39(3):185-91. PubMed ID: 24253788
    [Abstract] [Full Text] [Related]

  • 9. Vertebral osteolysis originating from subchondral cyst end plate defects in transforaminal lumbar interbody fusion using rhBMP-2. Report of two cases.
    Balseiro S, Nottmeier EW.
    Spine J; 2010 Jul 01; 10(7):e6-e10. PubMed ID: 20488766
    [Abstract] [Full Text] [Related]

  • 10. Revision surgery after interbody fusion with rhBMP-2: a cautionary tale for spine surgeons.
    Rodgers SD, Marascalchi BJ, Grobelny BT, Smith ML, Samadani U.
    J Neurosurg Spine; 2013 Jun 01; 18(6):582-7. PubMed ID: 23560709
    [Abstract] [Full Text] [Related]

  • 11. Minimally invasive transforaminal lumbar interbody fusion: one surgeon's learning curve.
    Nandyala SV, Fineberg SJ, Pelton M, Singh K.
    Spine J; 2014 Aug 01; 14(8):1460-5. PubMed ID: 24290313
    [Abstract] [Full Text] [Related]

  • 12. RhBMP-2-induced radiculitis in patients undergoing transforaminal lumbar interbody fusion: relationship to dose.
    Villavicencio AT, Burneikiene S.
    Spine J; 2016 Oct 01; 16(10):1208-1213. PubMed ID: 27343729
    [Abstract] [Full Text] [Related]

  • 13. Complications with recombinant human bone morphogenetic protein-2 in posterolateral spine fusion associated with a dural tear.
    Glassman SD, Gum JL, Crawford CH, Shields CB, Carreon LY.
    Spine J; 2011 Jun 01; 11(6):522-6. PubMed ID: 20598649
    [Abstract] [Full Text] [Related]

  • 14. Complications associated with single-level transforaminal lumbar interbody fusion.
    Rihn JA, Patel R, Makda J, Hong J, Anderson DG, Vaccaro AR, Hilibrand AS, Albert TJ.
    Spine J; 2009 Aug 01; 9(8):623-9. PubMed ID: 19482519
    [Abstract] [Full Text] [Related]

  • 15. Adjacent vertebral body osteolysis with bone morphogenetic protein use in transforaminal lumbar interbody fusion.
    Helgeson MD, Lehman RA, Patzkowski JC, Dmitriev AE, Rosner MK, Mack AW.
    Spine J; 2011 Jun 01; 11(6):507-10. PubMed ID: 21729801
    [Abstract] [Full Text] [Related]

  • 16. Safety of transforaminal lumbar interbody fusion and intervertebral recombinant human bone morphogenetic protein-2.
    Villavicencio AT, Burneikiene S, Nelson EL, Bulsara KR, Favors M, Thramann J.
    J Neurosurg Spine; 2005 Dec 01; 3(6):436-43. PubMed ID: 16381205
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Nerve injury and recovery after lateral lumbar interbody fusion with and without bone morphogenetic protein-2 augmentation: a cohort-controlled study.
    Lykissas MG, Aichmair A, Sama AA, Hughes AP, Lebl DR, Cammisa FP, Girardi FP.
    Spine J; 2014 Feb 01; 14(2):217-24. PubMed ID: 24269858
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Neurologic impairment from ectopic bone in the lumbar canal: a potential complication of off-label PLIF/TLIF use of bone morphogenetic protein-2 (BMP-2).
    Wong DA, Kumar A, Jatana S, Ghiselli G, Wong K.
    Spine J; 2008 Feb 01; 8(6):1011-8. PubMed ID: 18037352
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.